Continuous research has led to new drug developments, particularly disease-modifying ... FibroBiologics, Kyverna Therapeutics, GlaxoSmithKline, PolTREG, Cyxone, Biohaven Pharmaceuticals, HuniLife ...

One of her most recent updates is from New York, where she recently went with Shahid Kapoor. She posted a picture from a restaurant there and simply captioned it, "Vegan Trail". In the photo, two ...

LOS ANGELES, CALIFORNIA: Remember Rose's arrogant fiancé in 'Titanic'? The character named Cal was played by Billy Zane. Now 58, the Chicago-born actor has undergone impressive transformation to play ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...

Along with the new shot, the slideshow clip included several ... Using the carousel of images to pass along an important message, Abby and Brittany captioned the TikTok, "Don't forget to #vote!" ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand ...

“Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, ” said Emma Walmsley, CEO. Guidance: GSK reaffirms ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p2,610.00. The company’s shares opened today at p1,430.50.

Strong growth in speciality medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have now built into GSK's ...